PPAR and GST polymorphisms may predict changes in intellectual functioning in medulloblastoma survivors.

PPAR polymorphisms may predict intellectual outcome changes in children treated for medulloblastoma. Importantly, emerging evidence suggests that PPAR agonists may provide an opportunity to minimize the effects of treatment-related cognitive sequelae in these children.